Current status and trends of immune-related adverse events in lung cancer treated with immune checkpoint inhibitors: a bibliometric analysis of the past decade (2016–2025)

1

Immune checkpoint inhibitors (ICIs) are increasingly used in lung cancer treatment, but immune-related adverse events (irAEs) pose significant safety concerns.
2

A bibliometric analysis from 2016 to 2025 reveals a rising trend in publications on irAEs in lung cancer, with China leading in output.
3

Co-citation analysis identified key references, including landmark trials and guidelines on irAE management, highlighting major research themes.
4

Research hotspots have evolved from general safety in melanoma to lung cancer-specific irAEs and their long-term prognosis in recurrent cases.
5

The findings emphasize the need for further investigation into organ-specific high-risk irAEs and personalized intervention strategies in lung cancer.

1